$TARA reports 2022 financials and progress on transformative therapies.
Mar 8th 2023, 1:11 pm
Analyst Summary: Protara Therapeutics has announced its Q4 and full-year 2022 financial results that show cash, cash equivalents, and investments of $102.3 million as of December 31, 2022. The company is a clinical-stage firm that is engaged in the development of transformative therapies for the treatment of rare diseases and cancer. The company's lead product candidate TARA-002, an investigational cell-based therapy, is being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and data from the Phase 1a portion of the ADVANCED-1 trial of TARA-002 for the treatment of non-muscle invasive bladder cancer is expected in 2Q23. The company has also begun phase 2 clinical trial start-up activities for TARA-002 in lymphatic malformations, and trial initiation is expected in 2H23. The company's IV Choline Chloride is an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company is well-positioned to execute on its pipeline programs and looks forward to providing updates in due course. Quotes from CEO, Jesse Shefferman: "We believe we are well-positioned to successfully execute our pipeline programs and look forward to providing updates in due course...this year will be a particularly exciting time for Protara, With key data and milestones expected from our clinical programs for TARA-002." Forward-looking statements: Protara's development programs may not progress, the potential benefits of TARA-002 and IV Choline Chloride, the suitability of Protara's manufacturing operations for its development programs, the ability to initiate and complete clinical trials, and the commercial potential of the company's product candidates are subject to substa